Arvinas (ARVN) vs DiaMedica Therapeutics (DMAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
DiaMedica Therapeutics (DMAC) has outperformed Arvinas (ARVN) over the past year, gaining 15.0% versus a loss of 26.8%. Over five years, DMAC leads with a +88.3% price change compared with -91.8% for ARVN. Arvinas is the larger company by market cap ($449.7 million vs $408.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | DMAC |
|---|---|---|
| Share price | $6.97 | $7.57 |
| Market cap | $449.71M | $408.22M |
| 1-day change | -2.65% | -5.85% |
| YTD return | -41.23% | -4.90% |
| 1-year return | -26.79% | +15.05% |
| 5-year return | -91.79% | +88.31% |
| P/E ratio (TTM) | 26.81 | — |
| EPS (TTM) | $0.26 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | — |
| Revenue growth (YoY) | -0.30% | — |
| Net income (latest FY) | $-80.80M | $-32.77M |
| Operating margin | -45.13% | — |
| Net margin | -30.77% | — |
| 52-week high | $14.51 | $10.42 |
| 52-week low | $6.74 | $5.25 |
| Distance from 52-week high | -51.96% | -27.35% |
| Analyst consensus | buy | none |
| Avg. price target upside | +99.86% | +104.76% |
| Average volume | 800.32K | 182.81K |
| Shares outstanding | 64.52M | 53.93M |
| Employees | 246 | 35 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DMAC has outperformed ARVN by 41.8 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Healthcare · Biotechnology · 246 employees
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Healthcare · Biotechnology · 35 employees
ARVN vs DMAC FAQ
Which is bigger, Arvinas or DiaMedica Therapeutics?
Arvinas (ARVN) is larger, with a market capitalization of $449.71M compared with $408.22M for DiaMedica Therapeutics (DMAC).
Which stock has performed better over the past year, ARVN or DMAC?
DMAC returned +15.05% over the past 12 months, compared with -26.79% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and DiaMedica Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.